Skip to content

European researchers develop method of calculating short-term risk of HIV disease progression

T-20 increases tipranavir levels but does not increase risk of liver side-effects

Cognitive impairment common in people with HIV despite antiretroviral therapy

Switch to nevirapine safe for treatment-experienced patients with high CD4 cell counts

Patients with cryptococcus who start HAART may develop an IRIS up to three years later

Nelfinavir shows promise as a cancer therapy

Over one year of 3TC use associated with increased risk of diabetes for HIV-positive women

Patients with undetectable viral load, but a CD4 cell count below 200 may be able to stop PCP prophylaxis

Towards a comprehensive package of preventive and palliative care